Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

May 21, 2026 updated by: Merck Sharp & Dohme LLC

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).

Study Type

Interventional

Enrollment (Estimated)

490

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Argentina
      • Caba, Argentina, C1114AAN
        • Recruiting
        • FUNDALEU ( Site 0104)
        • Contact:
          • Study Coordinator
          • Phone Number: 5411 48771046
      • Córdoba, Argentina, X5016KEH
        • Recruiting
        • Hospital Privado Universitario de Córdoba ( Site 0107)
        • Contact:
          • Study Coordinator
          • Phone Number: +541569634187
      • Mendoza, Argentina, M5500AYB
        • Completed
        • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1118AAT
        • Recruiting
        • Hospital Aleman ( Site 0102)
        • Contact:
          • Study Coordinator
          • Phone Number: +541148277000
    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., Argentina, C1431FWO
        • Recruiting
        • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
        • Contact:
          • Study Coordinator
          • Phone Number: +541152990247
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Recruiting
        • Fundacion Estudios Clinicos ( Site 0112)
        • Contact:
          • Study Coordinator
          • Phone Number: +54 0341 238 4171
  • Australia
    • New South Wales
      • Sydney, New South Wales, Australia, 2747
        • Completed
        • Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Recruiting
        • Box Hill Hospital ( Site 0203)
        • Contact:
          • Study Coordinator
          • Phone Number: +611300342255
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Recruiting
        • Sir Charles Gairdner Hospital ( Site 0200)
        • Contact:
          • Study Coordinator
          • Phone Number: +61864573333
  • Brazil
      • Rio de Janeiro, Brazil, 20231-050
        • Recruiting
        • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
        • Contact:
          • Study Coordinator
          • Phone Number: +552132076564
      • São Paulo, Brazil, 01321-001
        • Recruiting
        • Hospital Paulistano - Amil Clinical Research ( Site 0311)
        • Contact:
          • Study Coordinator
          • Phone Number: +551130161340
      • São Paulo, Brazil, 01321-001
        • Active, not recruiting
        • BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
    • São Paulo
      • São Paulo, São Paulo, Brazil, 05403-000
        • Recruiting
        • Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
        • Contact:
          • Study Coordinator
          • Phone Number: 551145737543
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Recruiting
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
        • Contact:
          • Study Coordinator
          • Phone Number: 4035213723
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Recruiting
        • The Ottawa Hospital ( Site 0404)
        • Contact:
          • Study Coordinator
          • Phone Number: 613 737-7700
      • Toronto, Ontario, Canada, M5G 2M9
        • Recruiting
        • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
        • Contact:
          • Study Coordinator
          • Phone Number: 416-946-2827
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Recruiting
        • Jewish General Hospital ( Site 0400)
        • Contact:
          • Study Coordinator
          • Phone Number: 5143408222 x 24572
      • Montreal, Quebec, Canada, H1T 2M4
        • Recruiting
        • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
        • Contact:
          • Study Coordinator
          • Phone Number: 5142523400
  • China
    • Anhui
      • Hefei, Anhui, China, 230071
        • Recruiting
        • Anhui Provincial Hospital ( Site 2808)
        • Contact:
          • Study Coordinator
          • Phone Number: 13866173932
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100191
        • Recruiting
        • Peking University Third Hospital-Hematology ( Site 2827)
        • Contact:
          • Study Coordinator
          • Phone Number: 010-82266699
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400072
        • Active, not recruiting
        • The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
    • Guangdong
      • Guangzhou, Guangdong, China, 510060
        • Recruiting
        • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
        • Contact:
          • Study Coordinator
          • Phone Number: (+86)13719189172
    • Guangxi
      • Liuzhou, Guangxi, China, 545006
        • Recruiting
        • Liuzhou People's Hospital ( Site 2817)
        • Contact:
          • Study Coordinator
          • Phone Number: +8607722662950
      • Nanning, Guangxi, China, 530028
        • Recruiting
        • Guangxi Medical University Cancer Hospital ( Site 2814)
        • Contact:
          • Study Coordinator
          • Phone Number: +8607715323174
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Recruiting
        • Henan Cancer Hospital-hematology department ( Site 2802)
        • Contact:
          • Study Coordinator
          • Phone Number: 0371-65588007
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Recruiting
        • Wuhan Union Hospital ( Site 2816)
        • Contact:
          • Study Coordinator
          • Phone Number: +8618627091655
    • Hunan
      • Changsha, Hunan, China, 410011
        • Recruiting
        • The Second Xiangya Hospital of Central South University ( Site 2820)
        • Contact:
          • Study Coordinator
          • Phone Number: +8613975806137
      • Changsha, Hunan, China, 410013
        • Recruiting
        • Hunan Cancer Hospital ( Site 2822)
        • Contact:
          • Study Coordinator
          • Phone Number: 0731-88651669
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • Jiangsu Province Hospital ( Site 2823)
        • Contact:
          • Study Coordinator
          • Phone Number: 025-86211033
      • Xuzhou, Jiangsu, China, 221000
        • Active, not recruiting
        • The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Recruiting
        • The First Affiliated Hospital of Nanchang University ( Site 2815)
        • Contact:
          • Study Coordinator
          • Phone Number: 13970038386
    • Jilin
      • Changchun, Jilin, China, 130021
        • Recruiting
        • The First Hospital of Jilin University-Hematology ( Site 2803)
        • Contact:
          • Study Coordinator
          • Phone Number: 0431-88786014
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Recruiting
        • Fudan University Shanghai Cancer Center ( Site 2801)
        • Contact:
          • Study Coordinator
          • Phone Number: +8602164175590
      • Shanghai, Shanghai Municipality, China, 200040
        • Recruiting
        • Huashan Hospital, Fudan University ( Site 2821)
        • Contact:
          • Study Coordinator
          • Phone Number: 021-52889999
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Recruiting
        • West China Hospital Sichuan University ( Site 2810)
        • Contact:
          • Study Coordinator
          • Phone Number: +86028-85422114
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 301617
        • Recruiting
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
        • Contact:
          • Study Coordinator
          • Phone Number: +8615900265415
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310002
        • Recruiting
        • The First Affiliated Hospital, Zhejiang University ( Site 2826)
        • Contact:
          • Study Coordinator
          • Phone Number: 057187236114
  • Czechia
      • Hradec Králové, Czechia, 500 05
        • Recruiting
        • Fakultni nemocnice Hradec Kralove ( Site 0601)
        • Contact:
          • Study Coordinator
          • Phone Number: +420495832159
    • Brno-mesto
      • Brno, Brno-mesto, Czechia, 625 00
        • Recruiting
        • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
        • Contact:
          • Study Coordinator
          • Phone Number: +420532233642
  • Denmark
    • Central Jutland
      • Aarhus N, Central Jutland, Denmark, 8200
        • Completed
        • Aarhus University Hospital ( Site 0702)
    • North Denmark
      • Aalborg, North Denmark, Denmark, 9000
        • Recruiting
        • Aalborg Universitetshospital ( Site 0703)
        • Contact:
          • Study Coordinator
          • Phone Number: +45 97660000
    • Region Sjælland
      • Roskilde, Region Sjælland, Denmark, 4000
        • Recruiting
        • Sjaellands Universitetshospital Roskilde ( Site 0701)
        • Contact:
          • Study Coordinator
          • Phone Number: +45 46323200
    • Region Syddanmark
      • Odense C, Region Syddanmark, Denmark, 5000
        • Completed
        • Odense University Hospital ( Site 0705)
  • France
      • Paris, France, 75010
        • Recruiting
        • Hopital Saint Louis ( Site 0805)
        • Contact:
          • Study Coordinator
          • Phone Number: +33142499236
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, France, 06202
        • Recruiting
        • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
        • Contact:
          • Study Coordinator
          • Phone Number: +33 4 92 03 57 85
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite, Auvergne-Rhône-Alpes, France, 69495
        • Recruiting
        • Centre Hospitalier Lyon-Sud ( Site 0804)
        • Contact:
          • Study Coordinator
          • Phone Number: +33478864348
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, France, 13009
        • Recruiting
        • Institut Paoli-Calmettes ( Site 0803)
        • Contact:
          • Study Coordinator
          • Phone Number: +33491223537
    • Yvelines
      • Le Chesnay, Yvelines, France, 78150
        • Completed
        • Centre Hospitalier de Versailles ( Site 0809)
  • Germany
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Germany, 89081
        • Recruiting
        • Universitaetsklinikum Ulm. ( Site 0906)
        • Contact:
          • Study Coordinator
          • Phone Number: + 49 731 500 45901
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Germany, 50937
        • Recruiting
        • Universitaetsklinikum Koeln ( Site 0901)
        • Contact:
          • Study Coordinator
          • Phone Number: +4922147897046
      • Siegen, North Rhine-Westphalia, Germany, 57072
        • Completed
        • St. Marien-Krankenhaus Siegen ( Site 0914)
    • Saxony
      • Dresden, Saxony, Germany, 01307
        • Recruiting
        • Universitaetsklinikum Carl Gustav Carus ( Site 0902)
        • Contact:
          • Study Coordinator
          • Phone Number: 0049 351 458 5692
  • Hungary
      • Budapest, Hungary, 1122
        • Recruiting
        • Orszagos Onkologiai Intezet ( Site 1200)
        • Contact:
          • Study Coordinator
          • Phone Number: +3612248600
    • Baranya
      • Pécs, Baranya, Hungary, 7624
        • Recruiting
        • Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
        • Contact:
          • Study Coordinator
          • Phone Number: +3672536000
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Hungary, 4032
        • Recruiting
        • Debreceni Egyetem Klinikai Kozpont ( Site 1201)
        • Contact:
          • Study Coordinator
          • Phone Number: +3652255196
    • Szabolcs-Szatmár-Bereg
      • Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary, 4400
        • Recruiting
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
        • Contact:
          • Study Coordinator
          • Phone Number: +3642599700
  • Ireland
      • Dublin, Ireland, Dublin 9
        • Recruiting
        • Beaumont Hospital ( Site 2900)
        • Contact:
          • Study Coordinator
          • Phone Number: +35318092010
      • Limerick, Ireland, V94 F858
        • Recruiting
        • University Hospital Limerick ( Site 2903)
        • Contact:
          • Study Coordinator
          • Phone Number: +35361588320
  • Israel
      • Afula, Israel, 1834111
        • Recruiting
        • Ha Emek Medical Center ( Site 1305)
        • Contact:
          • Study Coordinator
          • Phone Number: 972-46494052
      • Beersheba, Israel, 8457108
        • Recruiting
        • Soroka Medical Center ( Site 1307)
        • Contact:
          • Study Coordinator
          • Phone Number: +97286403827
      • Haifa, Israel, 3109601
        • Recruiting
        • Rambam Medical Center ( Site 1301)
        • Contact:
          • Study Coordinator
          • Phone Number: +97247772547
      • Jerusalem, Israel, 9112001
        • Recruiting
        • Hadassah Ein Karem Jerusalem ( Site 1300)
        • Contact:
          • Study Coordinator
          • Phone Number: +97226778180
      • Ramat Gan, Israel, 5262001
        • Recruiting
        • Chaim Sheba Medical Center ( Site 1302)
        • Contact:
          • Study Coordinator
          • Phone Number: +97235308401
      • Rehovot, Israel, 76100
        • Recruiting
        • Kaplan Medical Center ( Site 1304)
        • Contact:
          • Study Coordinator
          • Phone Number: +97289441726
      • Tel Aviv, Israel, 6423906
        • Recruiting
        • Sourasky Medical Center ( Site 1303)
        • Contact:
          • Study Coordinator
          • Phone Number: +97236973782
  • Italy
      • Bari, Italy, 70124
        • Active, not recruiting
        • Istituto Tumori Giovanni Paolo II ( Site 1409)
      • Bologna, Italy, 40138
        • Recruiting
        • A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
        • Contact:
          • Study Coordinator
          • Phone Number: +390516363680
      • Brescia, Italy, 25123
        • Recruiting
        • ASST Spedali Civili di Brescia ( Site 1408)
        • Contact:
          • Study Coordinator
          • Phone Number: +39 0303996416
      • Milan, Italy, 20132
        • Recruiting
        • IRCCS Ospedale San Raffaele ( Site 1402)
        • Contact:
          • Study Coordinator
          • Phone Number: 00390226434797
      • Naples, Italy, 80131
        • Recruiting
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
        • Contact:
          • Study Coordinator
          • Phone Number: +39 0815903 382
      • Pavia, Italy, 27100
        • Recruiting
        • Fondazione IRCCS Policlinico San Matteo ( Site 1407)
        • Contact:
          • Study Coordinator
          • Phone Number: +39 0382503084
      • Reggio Emilia, Italy, 42123
        • Recruiting
        • IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
        • Contact:
          • Study Coordinator
          • Phone Number: +39 0522295654
      • Roma, Italy, 00161
        • Completed
        • Policlinico Umberto I ( Site 1404)
  • Poland
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Poland, 30-727
        • Recruiting
        • Pratia MCM Krakow ( Site 1601)
        • Contact:
          • Study Coordinator
          • Phone Number: 48 12 2954135
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Poland, 50-367
        • Recruiting
        • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
        • Contact:
          • Study Coordinator
          • Phone Number: +48717842576
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Poland, 02-781
        • Recruiting
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
        • Contact:
          • Study Coordinator
          • Phone Number: +48225462223
    • Opole Voivodeship
      • Opole, Opole Voivodeship, Poland, 45-061
        • Completed
        • Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
    • Pomeranian Voivodeship
      • Gdynia, Pomeranian Voivodeship, Poland, 81-519
        • Completed
        • Szpitale Pomorskie Sp. z o.o. ( Site 1600)
  • Romania
      • Brasov, Romania, 500052
        • Recruiting
        • Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
        • Contact:
          • Study Coordinator
          • Phone Number: 0729075567
      • Iași, Romania, 700483
        • Recruiting
        • Institutul Regional de Oncologie Iasi ( Site 1801)
        • Contact:
          • Study Coordinator
          • Phone Number: 40374278811
    • Bucharest
      • Bucharest, Bucharest, Romania, 030171
        • Recruiting
        • Spitalul Clinic Colțea ( Site 1805)
        • Contact:
          • Study Coordinator
          • Phone Number: 0040213874100
    • Constanța County
      • Ovidiu, Constanța County, Romania, 905900
        • Completed
        • Ovidius Clinical Hospital ( Site 1804)
  • South Korea
      • Seoul, South Korea, 03722
        • Recruiting
        • Severance Hospital Yonsei University Health System ( Site 2201)
        • Contact:
          • Study Coordinator
          • Phone Number: +82222281972
      • Seoul, South Korea, 06351
        • Recruiting
        • Samsung Medical Center ( Site 2200)
        • Contact:
          • Study Coordinator
          • Phone Number: +82234106548
  • Spain
      • Alicante, Spain, 03010
        • Recruiting
        • Hospital General Universitario de Alicante ( Site 2007)
        • Contact:
          • Study Coordinator
          • Phone Number: 965 93 30 00
      • Barcelona, Spain, 08035
        • Recruiting
        • Hospital Universitari Vall d'Hebron ( Site 2001)
        • Contact:
          • Study Coordinator
          • Phone Number: +34934893806
      • Madrid, Spain, 28041
        • Recruiting
        • Hospital Universitario 12 de Octubre ( Site 2003)
        • Contact:
          • Study Coordinator
          • Phone Number: +34917792809
      • Madrid, Spain, 28222
        • Recruiting
        • Hospital Puerta de Hierro ( Site 2009)
        • Contact:
          • Study Coordinator
          • Phone Number: +34911916000
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spain, 08908
        • Recruiting
        • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
        • Contact:
          • Study Coordinator
          • Phone Number: +34932607750
    • Castille and León
      • Salamanca, Castille and León, Spain, 37007
        • Recruiting
        • Hospital Universitario de Salamanca ( Site 2002)
        • Contact:
          • Study Coordinator
          • Phone Number: 34923 29 11 00x55974
    • La Coruna
      • A Coruña, La Coruna, Spain, 15006
        • Recruiting
        • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
        • Contact:
          • Study Coordinator
          • Phone Number: 34981178000
  • Switzerland
    • Canton Ticino
      • Bellinzona, Canton Ticino, Switzerland, 6500
        • Recruiting
        • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
        • Contact:
          • Study Coordinator
          • Phone Number: +41918118540
    • Canton of Bern
      • Bern, Canton of Bern, Switzerland, 3010
        • Recruiting
        • Inselspital Bern ( Site 2303)
        • Contact:
          • Study Coordinator
          • Phone Number: +41316329023
  • Turkey (Türkiye)
      • Ankara, Turkey (Türkiye), 06590
        • Recruiting
        • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
        • Contact:
          • Study Coordinator
          • Phone Number: +903125957099
      • Istanbul, Turkey (Türkiye), 34365
        • Completed
        • VKV Amerikan Hastanesi ( Site 2403)
      • Istanbul, Turkey (Türkiye), 34381
        • Recruiting
        • Sisli Florence Nightingale Hastanesi ( Site 2407)
        • Contact:
          • Study Coordinator
          • Phone Number: +90 542 502 50 75
      • Izmir, Turkey (Türkiye), 35340
        • Active, not recruiting
        • Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
    • Istanbul
      • Stanbul, Istanbul, Turkey (Türkiye), 34214
        • Active, not recruiting
        • Mega Medipol-Hematology ( Site 2406)
  • Ukraine
      • Kyiv, Ukraine, 03022
        • Recruiting
        • National Cancer Institute ( Site 2507)
        • Contact:
          • Study Coordinator
          • Phone Number: +380672091427
    • Cherkasy Oblast
      • Cherkassy, Cherkasy Oblast, Ukraine, 18009
        • Active, not recruiting
        • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine, 76008
        • Completed
        • Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukraine, 79044
        • Recruiting
        • Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
        • Contact:
          • Study Coordinator
          • Phone Number: +380322352276
  • United Kingdom
      • Manchester, United Kingdom, M20 4BX
        • Recruiting
        • The Christie NHS Foundation Trust ( Site 2602)
        • Contact:
          • Study Coordinator
          • Phone Number: 01619561217
    • Bristol, City of
      • Bristol, Bristol, City of, United Kingdom, BS2 8ED
        • Recruiting
        • Bristol Haematology and Oncology Centre ( Site 2610)
        • Contact:
          • Study Coordinator
          • Phone Number: 01173426733
    • England
      • Nottingham, England, United Kingdom, NG5 1PF
        • Recruiting
        • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
        • Contact:
          • Study Coordinator
          • Phone Number: +441159691169
      • Windsor, England, United Kingdom, SL4 3HD
        • Recruiting
        • GenesisCare - Windsor ( Site 2608)
        • Contact:
          • Study Coordinator
          • Phone Number: +447989474250
    • London, City of
      • London, London, City of, United Kingdom, W1G 6AD
        • Recruiting
        • Sarah Cannon Research Institute UK ( Site 2612)
        • Contact:
          • Study Coordinator
          • Phone Number: 02032195234
    • Oxfordshire
      • Oxford, Oxfordshire, United Kingdom, OX4 6LB
        • Recruiting
        • GenesisCare - Oxford ( Site 2607)
        • Contact:
          • Study Coordinator
          • Phone Number: +447989474250
    • Suffolk
      • Newmarket, Suffolk, United Kingdom, CB8 7XN
        • Recruiting
        • GenesisCare - Cambridge ( Site 2611)
        • Contact:
          • Study Coordinator
          • Phone Number: 01223 655145
    • Surrey
      • Sutton, Surrey, United Kingdom, SM2 5PT
        • Recruiting
        • The Royal Marsden NHS Foundation Trust. ( Site 2606)
        • Contact:
          • Study Coordinator
          • Phone Number: 020 8642 6011
  • United States
    • Arkansas
      • Springdale, Arkansas, United States, 72762
        • Recruiting
        • Highlands Oncology Group ( Site 2728)
        • Contact:
          • Study Coordinator
          • Phone Number: 479-872-8130
    • California
      • La Jolla, California, United States, 92093-0698
        • Recruiting
        • University of California San Diego Moores Cancer Center ( Site 2717)
        • Contact:
          • Study Coordinator
          • Phone Number: 858-534-5201
      • Torrance, California, United States, 90502
        • Completed
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
    • Colorado
      • Denver, Colorado, United States, 80218
        • Recruiting
        • Colorado Blood Cancer Institute ( Site 2726)
        • Contact:
          • Study Coordinator
          • Phone Number: 720-754-4800
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Completed
        • The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Active, not recruiting
        • Mayo Clinic - Rochester ( Site 2706)
    • New Jersey
      • East Brunswick, New Jersey, United States, 08816
        • Recruiting
        • Astera Cancer Care ( Site 2732)
        • Contact:
          • Study Coordinator
          • Phone Number: 732-672-6405
      • Hackensack, New Jersey, United States, 07601
        • Recruiting
        • John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
        • Contact:
          • Study Coordinator
          • Phone Number: 551-996-3003
    • North Dakota
      • Fargo, North Dakota, United States, 58102
        • Completed
        • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
    • Texas
      • Dallas, Texas, United States, 75390
        • Recruiting
        • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
        • Contact:
          • Study Coordinator
          • Phone Number: 972-695-9450
    • Washington
      • Spokane, Washington, United States, 99208
        • Recruiting
        • Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
        • Contact:
          • Study Coordinator
          • Phone Number: 509-462-2273

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
  • Has a life expectancy of at least 3 months, based on the investigator assessment
  • Has the ability to swallow and retain oral medication
  • Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Has adequate organ function
  • Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
  • Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
  • Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART

Part 1 and Part 2 (Cohorts A to C and J)

  • Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with

    • At least 2 lines of prior therapy (Part 1 only)
    • Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines
    • Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive
    • Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy
    • Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J
    • Has active disease for CLL/SLL clearly documented to initiate therapy
    • For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)

Part 2 (Cohorts D to G)

- Has a confirmed diagnosis of and meets the following prior therapy requirements:

  • Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)
  • Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)
  • Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen
  • Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)
  • Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan
  • Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening

Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi

  • Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease
  • Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%
  • Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival

Exclusion Criteria:

  • Has active HBV/HCV infection (Part 1 and Part 2)
  • Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
  • Has active central nervous system (CNS) disease
  • Has an active infection requiring systemic therapy
  • Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • Has any clinically significant gastrointestinal abnormalities that might alter absorption
  • History of severe bleeding disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Nemtabrutinib
Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.
Drug: Nemtabrutinib
Nemtabrutinib tablets administered orally QD.
Other Names:
  • MK-1026
  • ARQ 531

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
Time Frame: Up to ~56 days (Cycles 1-2, cycle = 28 days)
DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting >7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for >1 week (with exceptions); missing >25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity.
Up to ~56 days (Cycles 1-2, cycle = 28 days)
Part 1: Number of participants experiencing adverse events (AEs)
Time Frame: Up to ~71 months
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.
Up to ~71 months
Part 1: Number of participants discontinuing study treatment due to AEs
Time Frame: Up to ~42 months
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1.
Up to ~42 months
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
Time Frame: Up to ~61 months
ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.
Up to ~61 months
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
Time Frame: Up to ~61 months
ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography [CT]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters [SPD] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.
Up to ~61 months
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
Time Frame: Up to ~71 months
ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal).
Up to ~71 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part 1: Area Under the Curve (AUC) of Nemtabrutinib
Time Frame: At designated time points (up to ~57 days)
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.
At designated time points (up to ~57 days)
Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
Time Frame: At designated time points (up to ~57 days)
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.
At designated time points (up to ~57 days)
Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
Time Frame: At designated time points (up to ~57 days)
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.
At designated time points (up to ~57 days)
Part 2: AUC of Nemtabrutinib
Time Frame: At designated time points (up to ~57 days)
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.
At designated time points (up to ~57 days)
Part 2: Cmin of Nemtabrutinib
Time Frame: At designated time points (up to ~57 days)
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.
At designated time points (up to ~57 days)
Part 2: Cmax of Nemtabrutinib
Time Frame: At designated time points (up to ~57 days)
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.
At designated time points (up to ~57 days)
Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
Time Frame: Up to ~71 months
ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.
Up to ~71 months
Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
Time Frame: Up to ~71 months
For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.
Up to ~71 months
Part 2: Number of participants experiencing AEs
Time Frame: Up to ~61 months
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.
Up to ~61 months
Part 2: Number of participants discontinuing study treatment due to AEs
Time Frame: Up to ~42 months
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2.
Up to ~42 months
Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
Time Frame: Up to ~61 months
For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.
Up to ~61 months
Part 2: DOR per Lugano criteria 2014 as assessed by ICR
Time Frame: Up to ~61 months
For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.
Up to ~61 months
Part 2: DOR per IWWM criteria 2014 as assessed by ICR
Time Frame: Up to ~61 months
For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal).
Up to ~61 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Merck Sharp & Dohme LLC

Investigators

  • Study Director: Medical Director, Merck Sharp & Dohme LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 5, 2021

Primary Completion (Estimated)

January 4, 2029

Study Completion (Estimated)

January 4, 2029

Study Registration Dates

First Submitted

January 25, 2021

First Submitted That Met QC Criteria

January 25, 2021

First Posted (Actual)

January 28, 2021

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1026-003
  • MK-1026-003 (Other Identifier: MSD)
  • 2020-002324-36 (EudraCT Number)
  • U1111-1290-4004 (Registry Identifier: UTN)
  • 2023-504931-42-00 (Registry Identifier: EU CT)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-Hodgkins Lymphoma

Clinical Trials on Nemtabrutinib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe